- Research works
- 98 ▼ 14% vs 2013–17
- Citations
- 421 4.3 per fractional work
- Top-10% rate
- 9.3% record average 16.5%
- Open access
- 24% world 28%
Not ranked overall: Huahai Pharmaceutical (China) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Chemistry, 8.8×. Every wedge is a field page.
- Chemistry 8.8×
- Pharmacology, Toxicology and Pharmaceutics 8.3×
- Chemical Engineering 6.3×
- Biochemistry, Genetics and Molecular Biology 5.2×
- Agricultural and Biological Sciences 1.6×
- Medicine 1.4×
- Materials Science 1.1×
- Engineering 0.7×
- Immunology and Microbiology 0.6×
- Environmental Science 0.4×
- Earth and Planetary Sciences 0.4×
- Energy 0.2×
- Mathematics 0.2×
- Computer Science 0.1×
Which keywords describe research at Huahai Pharmaceutical (China)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Cancer, Transcriptional Regulation, Cell Proliferation, Epigenetic Regulation, Arginine Methylation, Protein Arginine Methyltransferases, Cancer Therapy and Biomarkers.
- Mass Spectrometry
- Oxidative Stress
- Cancer Therapy
- Antioxidant
- Arginine Methylation
- Inflammation
- Transcriptional Regulation
- Cancer
- Cell Proliferation
- Epigenetic Regulation
- Protein Arginine Methyltransferases
- Biomarkers
- Method Validation
- Homologous Recombination
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 14 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 14 words, with their numbers
- Cancer3▲ 8.8×11 topics
- Transcriptional Regulation2▲ 46×3 topics
- Cell Proliferation2▲ 76×2 topics
- Inflammation2▲ 3.1×10 topics
- Epigenetic Regulation1▲ 25×2 topics
- Arginine Methylation1▲ 190×1 topic
- Protein Arginine Methyltransferases1▲ 190×1 topic
- Antioxidant1▲ 6.6×7 topics
- Biomarkers1▲ 6.7×6 topics
- Cancer Therapy1▲ 8.1×5 topics
- Method Validation1▲ 75×2 topics
- Oxidative Stress1▲ 2.7×8 topics
- Homologous Recombination1▲ 86×2 topics
- Mass Spectrometry1▲ 25×3 topics
Which research topics does Huahai Pharmaceutical (China) publish most on?
By volume in 2022–2025: Cancer-related gene regulation, Prostate Cancer Treatment and Research, Analytical Methods in Pharmaceuticals and HIV/AIDS drug development and treatment.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer-related gene regulation Molecular Biology 1 works
- 2 Prostate Cancer Treatment and Research Pulmonary and Respiratory Medicine 1 works
- 3 Analytical Methods in Pharmaceuticals Analytical Chemistry 1 works
- 4 HIV/AIDS drug development and treatment Infectious Diseases 0 works
- 5 Garlic and Onion Studies Plant Science 0 works
- 6 DNA Repair Mechanisms Molecular Biology 0 works
- 7 Structural Engineering and Vibration Analysis Civil and Structural Engineering 0 works
- 8 Analytical Chemistry and Sensors Bioengineering 0 works
- 9 Plant Physiology and Cultivation Studies Plant Science 0 works
- 10 PARP inhibition in cancer therapy Oncology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Huahai Pharmaceutical (China)'s research output changed?
Output in 2018–2022 was 14% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Linhai
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.